FDA Places Clinical Hold on REGENXBIO’s Gene Therapy for Hunter Syndrome

FDA places clinical hold on REGENXBIO’s RGX-121 for Hunter Syndrome after asymptomatic spine MRI findings in 5 patients. Patients remain well; no near-term BLA resubmission.